Trials / Completed
CompletedNCT00720382
A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 703 (actual)
- Sponsor
- Meda Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.15% azelastine hydrochloride | 1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM |
| DRUG | Mometasone furoate | 200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM) |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-06-01
- Completion
- 2008-07-01
- First posted
- 2008-07-22
- Last updated
- 2015-05-21
- Results posted
- 2010-01-15
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00720382. Inclusion in this directory is not an endorsement.